Retatrutide 30 mg provides a high-concentration research format of the triple-agonist peptide Retatrutide. Recommended for laboratory settings conducting long-term or higher-volume studies.
Research Profile
- Triple-agonist activity across GIP, GLP-1, and glucagon receptors
- Studied in metabolic and energy-balance research models
- High-concentration format for extended studies
- QC verified by HPLC and mass spectrometry
Specifications
- Compound: Retatrutide (LY3437943)
- Dosage: 30 mg per vial
- Purity: ≥ 98% (HPLC)
- Form: Lyophilized powder
- Storage: 2–8 °C (lyophilized); –20 °C (reconstituted)
For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
